HR Execs on the Move

Tranquis Therapeutics

www.tranquis.com

 
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.tranquis.com
  • 951 Mariners Island Blvd Suite 300
    San Mateo, AB USA 94404
  • Phone: 650.684.8950

Executives

Name Title Contact Details
Sanjay Kakkar
President and Chief Executive Officer Profile

Similar Companies

eNeura Therapeutics

eNeura Therapeutics is a Medical Device company located in 240 N. Wolfe Rd., Sunnyvale, CA, United States.

AmnioLife

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.

Cutanix Corporation

Cutanix Corporation is a Franksville, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cleartrails

Cleartrails is a Villa Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seraxis

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies.